PRESS RELEASE: Dapagliflozin As Add On Therapy To -2-

26th Jun 2010 19:45

Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of $32.8 billion in 2009. In the United States, AstraZeneca is a $14.8 billion healthcare business. For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com or call 1-800-AZandMe (292-6363). CONTACT: Media: Bristol-Myers Squibb Ken Dominski, +1 609-252-5251 [email protected] or AstraZeneca Jim Minnick, +1 302-885-5135 [email protected] or Investors: Bristol-Myers Squibb John Elicker, +1 609-252-4611 [email protected] or AstraZeneca Karl Hard, +44-20-7304-5322 [email protected] or AstraZeneca Clive Morris, +44-207-304-5084 [email protected] SOURCE: Bristol-Myers Squibb Copyright Business Wire 2010 Order free Annual Report for AstraZeneca UK Ltd Visit http://djnweurope.ar.wilink.com/?ticker=GB0009895292 or call +44 (0)208 391 6028 (END) Dow Jones Newswires June 26, 2010 14:45 ET (18:45 GMT)